Literature DB >> 23172565

Operative intercostal chest drain is not required following extrapleural or transpleural esophageal atresia repair.

Saravanakumar Paramalingam1, David M Burge, Michael P Stanton.   

Abstract

BACKGROUND: Approximately half of the United Kingdom patients undergoing esophageal atresia (OA) repair have an operative intercostal chest drain (ICD) placed (2008 British Association of Pediatric Surgeons Congenital Anomalies Surveillance Study data). We reviewed our experience of OA repairs to evaluate if an ICD placement is necessary.
METHODS: Patients with OA/distal tracheoesophageal fistula (TOF), treated between January 1990 and January 2010, were identified by retrospective review of a prospectively maintained electronic database and patient case notes. MAIN
RESULTS: A total of 112 consecutive patients were identified, of whom 107 were included (73 male). Five were excluded as no case notes were available. Median birth weight was 2,597 g (range 924 to 4,245 g) and median gestational age was 38 weeks (27 to 41 weeks). Median age at discharge was 22 days (3 to 440 days) and median follow-up was 3.5 years (0 to 18 years). Patients were analyzed in two groups-group 1 (n = 73) had an extrapleural (EP) repair, of which 23 had a pleural breach and group 2 (n = 34) had a purposeful transpleural (TP) approach (surgeon preference). Eleven patients (10%) had an operative ICD, of which six patients were in group 1 and five in group 2. These 11 patients had an uncomplicated postoperative course and all operative ICD were removed within 48 hours of surgery. Of the 96 patients that did not have an operative ICD, only 2 (2%) required postoperative intervention. One patient, in group 2, had a postoperative ICD inserted for a simple pneumothorax at 12 hours and removed at 48 hours. The other patient, in group 1, had a clinically detected anastomotic leak after 48 hours and required operative repair.
CONCLUSION: An operative ICD is not required following OA/distal TOF repair, whether the approach is EP or TP. ICD that were electively placed (in 10%) served no clinical purpose. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23172565     DOI: 10.1055/s-0032-1330845

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  6 in total

1.  Repair of oesophageal atresia by consultants and supervised trainees results in similar outcomes.

Authors:  C E Jones; R Smyth; S C Keys; O Ron; M P Stanton; L Kitteringham; R A Wheeler; N J Hall
Journal:  Ann R Coll Surg Engl       Date:  2020-05-21       Impact factor: 1.891

2.  A chest tube may not be needed after surgical repair of esophageal atresia and tracheoesophageal fistula.

Authors:  N Gawad; C Wayne; J Bass; A Nasr
Journal:  Pediatr Surg Int       Date:  2018-07-26       Impact factor: 1.827

3.  Immediate primary anastomosis for isolated oesophageal atresia: A single-centre experience.

Authors:  Ibrahim Uygun; Hikmet Zeytun; Selcuk Otcu
Journal:  Afr J Paediatr Surg       Date:  2015 Oct-Dec

4.  Retrospective analysis of pneumothorax after repair of esophageal atresia/tracheoesophageal fistula.

Authors:  Jiawei Zhao; Shen Yang; Siqi Li; Peize Wang; Yanan Zhang; Yong Zhao; Kaiyun Hua; Yichao Gu; Junmin Liao; Shuangshuang Li; Yongwei Chen; Jinshi Huang
Journal:  BMC Pediatr       Date:  2021-12-03       Impact factor: 2.125

5.  Necessity of Prophylactic Extrapleural Chest Tube During Primary Surgical Repair of Esophageal Atresia: A Systematic Review and Meta-Analysis.

Authors:  Martin Riis Ladefoged; Steven Kwasi Korang; Simone Engmann Hildorf; Jacob Oehlenschlæger; Susanne Poulsen; Magdalena Fossum; Ulrik Lausten-Thomsen
Journal:  Front Pediatr       Date:  2022-03-18       Impact factor: 3.418

6.  Predictors of histopathological esophagitis in infants and adolescents with esophageal atresia within a national follow-up programme.

Authors:  Felipe Donoso; Anna Beckman; Andrei Malinovschi; Helene Engstrand Lilja
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.